Allakos — Investor Day (February 2019)
86 slides from Allakos's investor day presentation, Feb 19, 2019
Slide 1: Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases
Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases R&D Analyst Day Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos” or the “Company”); the generation of future value; business strat
Slide 3: Allakos R&D Day Agenda
Allakos R&D Day Agenda Robert Alexander, PhD Introductions AK002 12:00 – 12:45 PM Henrik Rasmussen, MD PhD Review of Clinical Program 12:45 – 1:00 PM Marcus Maurer, MD Indolent Systemic Mastocytosis Phase 1 Chronic Urticaria Phase 2a 1:00 – 1:40 PM Q&A 1:40 – 2:00 PM
Slide 4: AK002: Introduction
Robert Alexander, PhD CEO – Allakos, Inc. AK002: Introduction
Slide 5: Executive Summary
Executive Summary AK002 has shown clinical activity in multiple mast cell diseases 3 forms of chronic urticaria (CU) Indolent systemic mastocytosis (ISM) AK002 depletes eosinophils Previously shown and confirmed in all studies to date Strong mechanistic and clinical support for AK002 activity in EG,
Slide 6: Mast Cells and Eosinophils: Effector Cells Central to Inflammatory Responses
Mast Cells and Eosinophils: Effector Cells Central to Initiating and Maintaining Inflammatory Responses Found at the Internal/External Interface of the Body In particular, in tissues and surrounding blood vessels and peripheral nerves Produce a Broad Range of Inflammatory Mediators Vasoactive amines
Slide 7: AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils
AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response AK002 Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis AK002
Slide 8: Mast Cells and Eosinophils are Key Drivers of Atopic & Inflammatory Disease
Mast Cells and Eosinophils are Key Drivers of Atopic & Inflammatory Disease T Cell B Cell Activated B Cell Mast Cell IgE Activation and Recruitment of Other Immune Cells and Tissue Inflammation Macrophage Eosinophil Neutrophil Allergens Smooth Muscle Neuron Epithelium ACUTE AND CHRONIC INFLAMMATION
Slide 9: Eosinophils and Mast Cells Play a Significant Role in Many Diseases
Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Gastroenteritis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTES
Slide 10: Current AK002 Development Status
AK002 Preclinical Phase 1 Phase 2 Data Expected Eosinophilic Gastritis Mid 2019 Chronic Urticaria Presented Today Indolent Systemic Mastocytosis Presented Today Severe Allergic Conjunctivitis Q1 / Early Q2 2019 Current AK002 Development Status
Slide 11: Development of AK002 for Eosinophilic Gastrointestinal Diseases
Development of AK002 for Eosinophilic Gastrointestinal Diseases
Slide 12: Eosinophilic Gastrointestinal Diseases (EGIDs)
Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM/ SMALL INTESTINE Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Gastroenteritis (EGE) = US Prevalence ~20-25K ~25K ~200K EG, EGE, EoE Chronic Eosinophilic Inflammation of the Stomach, Small Intestine,
Slide 13: EoE and EG Biopsies Have Elevated Eosinophils & Mast Cells
EoE and EG Biopsies Have Elevated Eosinophils & Mast Cells * p<0.05 SOURCE: Youngblood B, et al. Gastroenterology. 2018; DDW Late Breaking Presentation. Eosinophils 10 8 6 4 2 0 Mast Cells 15 10 5 0 Mast Cells 12 8 4 0 Eosinophils 12 8 4 0 % of CD45+ Viable Cells Esophagus Stomach Normal EoE Normal
Slide 14: Siglec-8 is Expressed on Eosinophils and Mast Cells in EoE and EG
Siglec-8 is Expressed on Eosinophils and Mast Cells in EoE and EG EG Biopsies Mast Cells Eosinophils Siglec-8 CD117 Siglec-8 CD117 EoE Biopsies Mast Cells Eosinophils SOURCE: Youngblood B, et al. Gastroenterology. 2018; DDW Late Breaking Presentation. Siglec-8 is expressed in disease tissue
Slide 15: IgE appears to be a driver of mast cell activation
IgE appears to be a driver of mast cell activation Eos and Mast Cells Are Activated in EG, EGE, and EoE Biopsies CD63 3000 2000 1000 0 150000 100000 50000 0 IgE 8000 4000 2000 0 6000 CD49d 60000 40000 20000 0 CD11b Eosinophils Mast Cells Normal EG Normal EG Normal EG Normal EG * p<0.05 SOURCE: Young
Slide 16: AK002 Inhibits Anaphylaxis in a Humanized Mouse Model
AK002 Inhibits Anaphylaxis in a Humanized Mouse Model CLINICAL SYMPTOM SCORE Time (min) Clinical Score CORE TEMPERATURE Time (min) ∆ Temperature ∘C Isotype Control + IgE + Allergen AK002 + IgE + Allergen SOURCE: Youngblood B, et al. Annals of Allergy, Asthma and Immunology. 2018; Distinguished Oral
Slide 17: AK002 Reduces Eos & Mast Cell Infiltration in EG/EGE Mouse Model
AK002 Reduces Eos & Mast Cell Infiltration in EG/EGE Mouse Model EG + EGE Mouse Model: Eosinophil and Mast Cell Counts BLOOD Sham ISO AK002 Sham ISO AK002 Sham ISO AK002 Sham ISO AK002 Sham ISO AK002 STOMACH SMALL INTESTINE SOURCE: Youngblood B, et al. Gastroenterology. 2018; DDW Late Breaking Prese
Slide 18: AK002 Reduces Chemokines in EG/EGE Mouse Model
EG + EGE Mouse Model: Chemokine Expression AK002 Reduces Chemokines in EG/EGE Mouse Model CCL5 CCL2 Relative mRNA Expression Sham ISO AK002 CCL17 Relative mRNA Expression Sham ISO AK002 Relative mRNA Expression Sham ISO AK002 SOURCE: Youngblood B, et al. Gastroenterology. 2018; DDW Late Breaking Pre
Slide 19: Summary
Summary Mast cells and eosinophils are key drivers of atopic & inflammatory diseases AK002, an anti-Siglec-8 monoclonal antibody, depletes eosinophils and inhibits mast cells Strong mechanistic, histologic, and clinical support for AK002 activity in EG, EGE, and EoE Siglec-8 is constitutively expres
Slide 20: Allakos R&D Day Agenda
Allakos R&D Day Agenda Robert Alexander, PhD Introductions AK002 12:00 – 12:45 PM Henrik Rasmussen, MD PhD Review of Clinical Program 12:45 – 1:00 PM Marcus Maurer, MD Indolent Systemic Mastocytosis Phase 1 Chronic Urticaria Phase 2a 1:00 – 1:40 PM Q&A 1:40 – 2:00 PM
Slide 21: AK002 Clinical Development Overview
AK002 Clinical Development Overview Henrik Rasmussen, MD PhD
Slide 22: Current AK002 Development Status
AK002 Preclinical Phase 1 Phase 2 Data Expected Eosinophilic Gastritis Mid 2019 Chronic Urticaria Presented Today Indolent Systemic Mastocytosis Presented Today Severe Allergic Conjunctivitis Q1 / Early Q2 2019 Current AK002 Development Status
Slide 23: AK002 Showed Sustained Depletion of Eosinophils in Healthy Volunteers in Phase 1
AK002 Showed Sustained Depletion of Eosinophils in Healthy Volunteers in Phase 1 Study * No patients randomized to Placebo **Blood eosinophils evaluated Day 1, 2, 4, 7, 14, 28, 56, 84, 112 PLACEBO AK002 AK002 Dose Cohort (mg/kg) Pre-Dose 1hr Post-Dose Pre-Dose 1hr Post-Dose Minimal Duration Eos Depl
Slide 24: Eosinophilic Gastritis ± Gastroenteritis Phase 2
Eosinophilic Gastritis ± Gastroenteritis Phase 2 Study Design Key Endpoints Status Randomized, DB, placebo-controlled study 60 Patients – 3 arms 20 patients 0.3, 1.0,1.0, 1.0 mg/kg 20 patients 0.3, 1.0, 3.0, 3.0 mg/kg 20 patients placebo Multiple doses (x4) 9 month safety exposure trial Primary Chan
Slide 25: Severe Allergic Conjunctival Disease Phase 1b
Severe Allergic Conjunctival Disease Phase 1b Study Design Key Endpoints Status Open-label, pilot study 30 patients – 3 cohorts Atopic keratoconjunctivitis Vernal keratoconjunctivitis Perennial allergic conjunctivitis Dosed once monthly for 6 months 6 month follow up 0.3 mg/kg starting dose, followe
Slide 26: ISM Phase 1 Multiple Dose
ISM Phase 1 Multiple Dose Study Design Key Endpoints Status Open-label, pilot study 11 ISM patients Three week screening period 6 Monthly Doses: 1.0 mg/kg (cohort 9) and 1.0 then 1.0-10.0 mg/kg (cohort 10) Primary Safety and tolerability Complete Secondary Patient reported outcomes: MSQ (Allakos PRO
Slide 27: Chronic Urticaria Phase 2a
Chronic Urticaria Phase 2a Study Design Key Endpoints Status Open-label, pilot study 47 patients – 4 cohorts Xolair naïve CSU Xolair refractory CSU Cholinergic urticaria Symptomatic Dermographism One month screening period Dosed once monthly for 6 months 8 weeks safety follow up 0.3 mg/kg starting d
Slide 28: AK002 Safety Summary
AK002 Safety Summary No adverse findings in short- and long-term toxicity studies PRECLINICAL Approximately 140 subjects exposed to drug in clinical studies Generally well-tolerated First infusion approximately 4 hours, subsequent infusions 2-3 hours Mild to moderate infusion reactions (flushing, fe
Slide 29: Professor Marcus Maurer, MD
Professor Marcus Maurer, MD TITLE:Professor of Dermatology and Allergy Director of Research - Allergie Centrum Charité INSTITUTION:Charité Universitätsmedizin Berlin SPECIALTY:Dermatology, Allergy and Immunology FOCUS:Urticaria, Mastocytosis, Angioedema, Pruritus, Skin Infections, Allergic Diseases
Slide 30: Allakos R&D Day Agenda
Allakos R&D Day Agenda Robert Alexander, PhD Introductions AK002 12:00 – 12:45 PM Henrik Rasmussen, MD PhD Review of Clinical Program 12:45 – 1:00 PM Marcus Maurer, MD Indolent Systemic Mastocytosis Phase 1 Chronic Urticaria Phase 2a 1:00 – 1:40 PM Q&A 1:40 – 2:00 PM
Slide 31: AK002 in Indolent Systemic Mastocytosis Topline Data
AK002 in Indolent Systemic Mastocytosis Topline Data
Slide 32: Indolent Systemic Mastocytosis (ISM)
Indolent Systemic Mastocytosis (ISM) Indolent Systemic Mastocytosis Disease Patients have increased numbers of mast cells throughout the body Symptoms due to increased release of mast cell mediators Symptoms Include itching, hives, flushing, diarrhea, headache, fatigue, difficulty concentrating, abd
Slide 33: What is mastocytosis?
What is mastocytosis?
Slide 34: Indolent Systemic Mastocytosis - Symptoms
Indolent Systemic Mastocytosis - Symptoms Diarrhea, Vomiting (23%) Weight loss (10%) Peptic Ulcers (4-7%) Pruritus (40%) Flushing (36%) Tachycardia (18%) Respiratory symptoms (< 5%) Fatigue, Fever (12%) Headache (10%)
Slide 35: Phase 1 Multiple Dose Study in Patients with ISM
Phase 1 Multiple Dose Study in Patients with ISM Design Key Endpoints Open-label 11 ISM patients 6 Monthly Doses: 1.0 mg/kg (cohort 9) and 1.0 then 1.0-10.0 mg/kg (cohort 10) Primary Safety and tolerability Secondary Patient reported outcomes: MSQ (Allakos ISM PRO) MAS2 (Charité ISM PRO) MC-QOL (Cha
Slide 36: ISM Study Key Inclusion/Exclusion Criteria
ISM Study Key Inclusion/Exclusion Criteria INCLUSION Adults (≥18 and ≤85 years old) Confirmed diagnosis of ISM based on World Health Organization (WHO) criteria Presence of at least 1 of the following ISM related symptoms: Flushing (at least 1 episode per week) Pruritus (minimum MAS score of 4) Diar
Slide 37: ISM Study Baseline Patient Characteristics
ISM Study Baseline Patient Characteristics Multi-dose Patients (N=12) Age, Median (Range) 47 (34-66) Female 75% Weight (kg), Median (Range) 71 (54-105) BMI, Median (Range) 26 (20-39) MSQ Total Symptom Score (0-90), Mean (Median)1 32.1 (33.3) MAS2 Total Symptom Score (0-36), Mean (Median)2 14.2 (15.7
Slide 38: Symptom Reduction by MSQ PRO
Symptom Reduction by MSQ PRO Measurement Baseline (0-10) Median %∆ Wk 21-22 to BL MSQ Symptom Scores, Itching Hives Flushing (#) Abdominal Pain Diarrhea Headache Fatigue Difficulty Concentrating Muscle Pain Joint Pain 3.7 4.2 4.1 3.4 2.9 3.7 5.1 3.9 3.6 3.4 -56% -38% -46% -60% -49% -50% -47% -59% -2
Slide 39: Symptom Reduction by MAS2 PRO
Symptom Reduction by MAS2 PRO Measurement Baseline (0-4) Median %∆ Wk 21-22 to BL MAS2 Symptom Scores, Itching Hives Flushing Abdominal Pain Diarrhea Headache Fatigue Difficulty Concentrating Bone-Joint-Muscle Pain 1.8 1.6 1.7 1.4 1.0 1.5 2.2 1.6 2.0 -53% -59% -57% -84% -72% -57% -22% -30% -22% MAS2
Slide 40: Improvement in Quality of Life
Improvement in Quality of Life MC-QoL Measurement Baseline (0-4) Median %∆ Day 145 to BL MC-QoL Scores (0-100), Symptoms Social Life / Functioning Emotions Skin 64 69 48 51 -39% -42% -57% -44% Symptoms: diarrhea, fatigue, headache, muscle or joint pain, difficulty concentrating; limited sleep, tired
Slide 41: ISM Patient Case Study
ISM Patient Case Study Patient reported significant resolution of her symptoms: GI, headache, and skin Would like to be back on AK002 Response to AK002 Medical History 43 year old woman Diagnosed with ISM in 1993 Suffered from severe ISM symptoms for over 20 years despite treatment Tried ranitidine,
Slide 42: ISM Patient Case Study
ISM Patient Case Study Skin CNS GI MSQ Total 98% reduction in skin domain (flushing, itching, and hives) 96% reduction in CNS domain (headache, difficulty concentrating, fatigue) 71% reduction in GI domain (abdominal pain and diarrhea) 1 month 3 months
Slide 43: ISM Phase 1: Safety Summary
ISM Phase 1: Safety Summary Generally well-tolerated All drug-related adverse events (AEs) were mild to moderate The most common AEs were mild-to-moderate infusion-related reactions (feeling hot, headache, erythema, fatigue, or dizziness) No drug related Serious Adverse Events
Slide 44: Conclusions for AK002 in ISM
Conclusions for AK002 in ISM Significant and consistent symptom and QoL improvements on AK002 Generally well-tolerated Results support further development in this indication
Slide 45: AK002 in Patients with Chronic Urticaria (CU) Topline Data
AK002 in Patients with Chronic Urticaria (CU) Topline Data
Slide 46: Overview of Chronic Urticaria
Overview of Chronic Urticaria Disease caused by the inappropriate activation of mast cells in the skin Symptoms include hives, edema, and severe itching Trigger: unknown 80% of urticarias Chronic Spontaneous Urticaria Trigger: increase in body temp 6% of urticarias Cholinergic Urticaria Trigger: phy
Slide 47: Slide 47
Slide 48: Itchy Wheals and/or Angioedema Chronic Urticaria
Itchy Wheals and/or Angioedema Chronic Urticaria
Slide 49: EAACI CU Treatment Guidelines
EAACI CU Treatment Guidelines SOURCE:Zuberbier et al. Allergy. 2018. Antihistamines Increase antihistamine dose (up to 4x) Antihistamines + Omalizumab Antihistamines + Cyclosporine If inadequate control If inadequate control If inadequate control (UCT<12 after 2-4 weeks) (UCT<12 after 2-4 weeks) (UC
Slide 50: CSU Epidemiology Estimate
CSU Epidemiology Estimate: ~800K to 1.7M US Patients Refractory to High Dose Antihistamines ~80% inadequate response to labeled dose of antihistamines ~60% inadequate response to increased dose of antihistamines SOURCES: Maurer et al. Allergy. 2011 Mar;66(3):317-30; Staevska et al. J Allergy Clin Im
Slide 51: Many Patients Have Inadequate Response to Xolair
Many Patients Have Inadequate Response to Xolair® Omalizumab Ligelizumab vs Omalizumab ASTERIA1 I+II Phase III (n=322) GLACIAL1 Phase III (n=252) Weller, Maurer et al.2 (n=54) Phase IIb3, (n=85) 12 Weeks 24 Weeks 8 Weeks 20 Weeks UCT (CR) - - 63% (300 mg) - UAS7 %Δ from BL -53% (150 mg) -70% (300 mg
Slide 52: Chronic Urticaria – Unmet Need
Chronic Urticaria – Unmet Need Significant number of patients suffer from chronic urticaria Often high disease burden to those afflicted Current therapies do not always achieve disease control There is a need for new drugs with novel mechanisms
Slide 53: Chronic Urticaria Phase 2a
Chronic Urticaria Phase 2a Study Design Key Endpoints Open-label 47 patients – 4 cohorts Xolair naïve CSU Xolair refractory CSU Cholinergic urticaria Symptomatic Dermographism One month screening period Dosed once monthly for 6 months 8 weeks safety follow up 0.3mg/kg starting AK002 dose; if tolerat
Slide 54: CU Phase 2a: Key Inclusion/Exclusion Criteria
CU Phase 2a: Key Inclusion/Exclusion Criteria INCLUSION Adults (≥18 and ≤85 years old) Body weight <125 Kg Diagnosis of CU for at least three months, refractory to antihistamine treatment in single or 4-fold dosage Uncontrolled CU (UCT <12) at the time of enrollment EXCLUSION Acute urticaria Concurr
Slide 55: Urticaria Disease Assessment Tools (1 of 2)
Urticaria Disease Assessment Tools (1 of 2) URTICARIA CONTROL TEST (UCT) Measures disease control (symptoms and quality of life) Used in clinical practice Can be used in both chronic spontaneous urticaria and chronic inducible urticarias (e.g. cholinergic and symptomatic dermographism UCT and UAS7 r
Slide 56: Urticaria Disease Assessment Tools (2 of 2)
Urticaria Disease Assessment Tools (2 of 2) SDerm: UCT & Fric Test® Instrument with 4 pins of increasing heights to trigger hives Presence of hives reported for each pin Itch reported with validated visual analog scale UCT & provocation tests are recommended by EAACI CU Guidelines to assess Chronic
Slide 57: CU Study Baseline Patient Characteristics
CU Study Baseline Patient Characteristics XN (N=14) XR (N=12) CholU (N=11) SDerm (N=10) Total (N=47) Age, Median (Range) 66 (30-75) 29 (22-60) 33 (18-62) 27 (19-56) 42 (18-75) Female 93% 83% 55% 60% 75% Weight, Median (Range) 90 (50-124) 82 (57-115) 83 (66-112) 91 (70-112) 85 (50-124) BMI, Median (R
Slide 58: Chronic Spontaneous Urticaria (CSU) Xolair Naïve Cohort
Chronic Spontaneous Urticaria (CSU) Xolair® Naïve Cohort Patients with inadequate response to antihistamines (up to 4x dose)
Slide 59: High Levels of Response by UCT in CSU Xolair Naïve Patients
Endpoint Baseline Week 22 UCT Complete Response - 12/13 (92%) UCT Partial Response - 0/13 (0%) UCT No Response - 1/13 (8%) High Levels of Response by UCT in CSU Xolair® Naïve Patients
Slide 60: 75% Improvement in Mean UAS7 in Xolair Naïve Patients
75% Improvement in Mean UAS7 in Xolair® Naïve Patients Mean ± SEM UAS7 Score UAS7 -75% Baseline Week 22 Xolair® Naïve Patients (n=13)
Slide 61: High Response Rates on AK002 by UAS7 Measures
High Response Rates on AK002 by UAS7 Measures % of Responders at Week 22 Responder Rate by UAS7 Measures (10/13) (7/13) (7/13) (8/13) Xolair® Naïve Patients (n=13)
Slide 62: AK002 Xolair Naïve Summary
Endpoint Baseline Week 22 UCT Complete Response - 12/13 (92%) UCT Partial Response - 0/13 (0%) UCT No Response - 1/13 (8%) Average UAS7 Score 18.5 4.6 (-75%) Patients with UAS7 ≤ 6 0 (0%) 8/13 (62%) Patients with UAS7 =0 0 (0%) 7/13 (54%) Patients with ISS7 =0 0 (0%) 7/13 (54%) Patients with HSS7 =0
Slide 63: Chronic Spontaneous Urticaria (CSU) Xolair Refractory Cohort
Chronic Spontaneous Urticaria (CSU) Xolair® Refractory Cohort Patients with inadequate response to Xolair and antihistamines (up to 4x dose)
Slide 64: Xolair Refractory Cohort – Medical History
Xolair® Refractory Cohort – Medical History CSU Patients Refractory to Xolair® Inadequate disease control despite extensive use of Xolair® Prior Xolair® Treatment Experience Average treatment duration: ~10 months Treatment regimen: Xolair: up to 600 mg Antihistamine: up to 4x labeled dose Average UC
Slide 65: Xolair Refractory Patient Case
Xolair® Refractory Patient Case First improvement perceived after 2nd infusion (1.0 mg/kg) less hives and less itch By 4th dose, increased to 3.0 mg/kg with significant reduction of hives and itch and no flares By 5th dose, patient experienced full response: “I can sleep. It feels like I have my lif
Slide 66: Significant Disease Control in Xolair Refractory Patients on AK002
Significant Disease Control in Xolair® Refractory Pts on AK002 Endpoint Baseline Week 22 UCT Complete Response - 4/11 (36%) UCT Partial Response - 2/11 (18%) UCT No Response - 5/11 (45%)
Slide 67: 49% Improvement in UAS7 in Xolair Refractory Patients
49% Improvement in UAS7 in Xolair® Refractory Patients UAS7 %Δ from Baseline 1 Last observation carried forward % Change in UAS7 - Xolair® Refractory Patients (n=11) 28 24 36 29 35 26 35 28 18 35 21 0 5 8 8 16 14 21 18 14 30 27 BL= Week 221=
Slide 68: 8/11 (73%) XR Patients Achieved ∆UAS7≥10 (MID)
8/11 (73%) XR Patients Achieved ∆UAS7≥10 (MID) UAS7 %Δ from Baseline 1 Last observation carried forward 28 24 36 29 35 26 35 28 18 35 21 0 5 8 8 16 14 21 18 14 30 27 BL= Week 221= ∆UAS7 ≥10 (MID) % Change in UAS7 - Xolair® Refractory Patients (n=11)
Slide 69: 61% Improvement in UAS7 in Patients Who Received 6 AK002 Doses
61% Improvement in UAS7 in Xolair® Refractory Patients Who Received 6 AK002 Doses UAS7 %Δ from Baseline 1 Last observation carried forward: Four patients did not receive all 6 doses; 3 due to study extension, 1 patient died due to MI not related to drug Received 6 Doses Received <6 Doses1 28 24 36 2
Slide 70: Xolair Refractory: Mean UAS7 Score
Xolair® Refractory: Mean UAS7 Score All Xolair® Refractory (n=11) Baseline Week 22 LOCF Mean ± SEM UAS7 Score Received 6 Doses (n=7) Baseline Week 22 -61% Mean ± SEM UAS7 Score -49%
Slide 71: Meaningful Responses in CSU Xolair Refractory Patients
Meaningful Responses in CSU Xolair® Refractory Patients Endpoint Baseline Week 22 UCT Complete Response - 4/11 (36%) UCT Partial Response - 2/11 (18%) UCT No Response - 5/11 (45%) Average UAS7 Score 28.7 14.7 (-49%) Average UAS7, Patients with 6 doses 28.4 11.2 (-61%) Patients with UAS7 ≤ 6 0 (0%) 2
Slide 72: AK002 Clinical Activity Summary in CSU
AK002 Clinical Activity Summary in CSU CSU: XOLAIR® NAÏVE 12/13 (92%) patients achieved complete response (UCT) 9/13 (69%) patients reached complete response within 4 weeks (UCT) 75% mean reduction of symptoms by Week 22 (UAS7) 10/13 (77%) patients had no hives at Week 22 (HSS7=0) CSU: XOLAIR® REFRA
Slide 73: AK002 in CSU
AK002 in CSU AK002 demonstrated clear clinical activity in CSU Significant activity in patients that failed Xolair® Novel anti-Siglec-8 mechanism may have broader activity than existing therapies AK002 is well-positioned in CSU
Slide 74: Chronic Inducible Urticarias (CIndU)
Chronic Inducible Urticarias (CIndU) Symptomatic Dermographism Cohort Cholinergic Urticaria Cohort
Slide 75: 7/10 (70%) Response Rate in Symptomatic Dermographism
7/10 (70%) Response Rate in Symptomatic Dermographism Endpoint Baseline Week 22 UCT Complete Response - 4/10 (40%) UCT Partial Response - 3/10 (30%) UCT No Response - 3/10 (30%) FRIC Test Itch Response 0% 5/10 (50%) FRIC Test Hives Response (CFT) 0% 4/10 (40%)
Slide 76: 9/11 (82%) Complete Response Rate in Cholinergic Patients
9/11 (82%) Complete Response Rate in Cholinergic Patients Endpoint Baseline Week 22 UCT Complete Response - 9/11 (82%) UCT Partial Response - 0/11 (0%) UCT No Response - 2/11 (18%) PCE Exercise Test Response 0% 7/7 (100%)
Slide 77: 7/7 (100%) Response Rate by PCE Test in CholU Patients
7/7 (100%) Response Rate by PCE Test in CholU Patients 1Provocation - exercise on stationary bike elevates body temperature to trigger symptoms, positive response if occurring in ≤10 minutes from start 2Bad osteoarthritis of knees, patient had warm damp cloth applied that caused wheals and itching.
Slide 78: Cholinergic Patient Case
Cholinergic Patient Case Baseline Daily itchy hives on whole body except on face (severe: >50) Inadequate response on 4x dose of antihistamines On AK002 Treatment Complete response by 4th dose of AK002 4 weeks post last dose, symptoms returned Would like to be back on AK002 PCE Test: hives appear 5
Slide 79: CU Phase 2a Safety Summary
CU Phase 2a Safety Summary Generally well-tolerated No drug-related Serious Adverse Events Most common adverse event was mild to moderate infusion-related reactions (IRRs; flushing, feeling of warmth, headache, nausea, or dizziness) 34% IRRs rate on first infusion 4.7% IRRs rate on subsequent infusi
Slide 80: AK002 Has a Differentiated Profile in Chronic Urticaria
AK002 Has a Differentiated Profile in Chronic Urticaria Demonstrated activity in all forms of Chronic Urticaria tested Significant activity in patients refractory to Xolair® AK002 is well-positioned to be a biologic front-line treatment for Chronic Urticaria
Slide 81: Closing Remarks
Closing Remarks
Slide 82: Near Term Catalysts
Near Term Catalysts Q1/Q2 2019 Phase 1 Data Expected in Severe Allergic Conjunctivitis Mid 2019 Phase 2 Data Expected in Eosinophilic Gastritis Q1 2020 End of Phase 2 Meeting
Slide 83: Financing and IP
Financing and IP Cash and Investments as of September 30, 2018 $193.5M Q3 2018 Operating Expenses $12.0M ($30.2M YTD) AK002 US patents run until 2035 Lonza currently manufactures AK002 at commercial scale
Slide 84: Conclusions
Conclusions AK002 has shown clinical activity in multiple mast cell diseases 3 forms of chronic urticaria (CU) Indolent systemic mastocytosis (ISM) AK002 depletes eosinophils Previously shown and confirmed in all studies to date Strong mechanistic and clinical support for AK002 activity in EG, EGE,
Slide 85: Allakos
Alakos ji
Slide 86: Thank you
Beg) Thank you Allakos